Table 1.

Reversions as a mechanism of PARPi resistance detectable in cfDNA.

Sample (WES)	Gene	Initial mutation	Reversion mutation (VAF in exome)	Findings in cfDNA
EVO-009–001-Bx	BRCA1	Somatic p.L631Qfs*4a	c.1509_2366del; p.S425_C712fs	Confirmed in cfDNA (baseline and end of treatment)
EVO-009–006-Bx	BRCA2	Germline c.7480C>T	c.7480C>A (20% A allele)	Confirmed in cfDNA (baseline, on-trial and time of progression)
EVO-009–013-Bx	BRCA1	Germline c.2999del	c.3008_3009del (31.0%)	Confirmed in cfDNA (baseline only); amost somatic callers discard this as too many clustered events on short reads

Note: Somatic reversions previously detected in post-PARPi progressed tumor tissue using WES. Of these, three were successfully detected, and two had no evidence in cfDNA.

^aReversion detected but did not pass thresholds for high-confidence somatic mutation classification.